Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Actavis has received approval from the FDA to market propranolol hydrochloride extended-release capsules for the treatment of high blood pressure. Distribution of the product will commence immediately.
Subscribe to our email newsletter
Propranolol hydrochloride extended-release (ER) capsules are the generic equivalent of Wyeth Pharmaceuticals’s Inderal LA capsules and available in 60mg, 80mg, 120mg and 160mg doasage strengths. Propranolol ER capsules are indicated for the treatment of high blood pressure, long-term management of angina pectoris and prophylaxis of common migraine headaches.
Doug Boothe, executive VP of US commercial & administration at Actavis, said: “This launch is in line with our strategy to further grow our business in the controlled release product market and exemplifies our capability in controlled release oral solid products.”
Annual brand sales of Propranolol ER capsules in the US were approximately $192 million for the 12 months ending June 2007, according to IMS Health data.